National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Solid Tumors

Solid tumors are masses of abnormal tissue that are formed in organs or soft tissues and typically do not include fluid areas and cysts. These tumors can be benign (not contain cancer cells) or malignant (contain cancer cells). Solid tumors are typically named after the types of cells that compose them.

Examples of solid tumors:

  • Carcinomas: Cancer that begins in the skin or in tissues that line or cover internal organs
  • Sarcomas: Cancer of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue
  • Lymphomas: Cancer that begins in the immune cells of the lymphatic system

Leukemias (cancers of the blood) generally do not form solid tumors.

It is estimated that over 1,600,000* people in the United States will be newly diagnosed with a malignant solid tumor in 2013.

Treatment options for cancer vary depending on the type of cancer, stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013

Solid Tumor Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with solid tumors. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Solid Tumor
Phase II
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
NCI-13-C-0105, NCT01827384

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
NCI-12-C-0116, NCT01585428

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy
NCI-11-C-0146, NCT01339000

Principal Investigator:Referral Contact:
Claude SportèsZetta Blacklock
301-435-5280301-594-2056
bblacklock@mail.nih.gov
A Phase II Study Using Short-Term Cultured, CD8+-enriched Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers
NCI-10-C-0166, NCT01174121

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
NCI-09-C-0214, NCT00978250

Principal Investigator:Referral Contact:
James H. DoroshowJanelle Bingham
301-496-4291301-435-2715
jbingham@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
NCI-08-C-0121, NCT00670748

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
A Phase I/II Trial of IL-13-PE in Patients with Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
NCI-13-C-0046, NCT01766635

Principal Investigator:Referral Contact:
Electron KebebewErinn M. Hopkins
301-496-5049301-496-6457
erinn.hopkins@nih.gov
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes
NCI-12-C-0111, NCT01583686

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
NCI-11-C-0027, NCT01240590

Principal Investigator:Referral Contact:
Ann W. GramzaErinn M. Hopkins
301-827-4989301-496-6457
erinn.hopkins@nih.gov
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
NCI-11-C-0013, NCT01218867

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
A Phase I Trial of Weekly Indenoisoquinoline LMP400 in Adults With Relapsed Solid Tumors and Lymphomas
NCI-13-C-0080, NCT01794104

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Adults With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
NCI-13-C-0063, NCT01772004

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
A Phase I Study of Single-agent MK-1775, a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors
NCI-13-C-0032, NCT01748825

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression
NCI-13-C-0016, NCT01730118

Principal Investigator:Referral Contact:
Lauren V. WoodBrenda Roberson
301-402-0199301-435-4733
broberson@mail.nih.gov
A Phase I and Pharmacokinetic Single-agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia, Select Solid Tumors, and Varying Degrees of Liver Dysfunction
NCI-12-C-0177, NCT01638533

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers
NCI-12-C-0113, NCT01572493

Principal Investigator:Referral Contact:
Kevin ConlonTat’Yana Worthy
301-496-7417301-496-0499
worthyt@mail.nih.gov
Phase I Trial of Oral 5-Fluoro-2-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors
NCI-12-C-0066, NCT01534598

Principal Investigator:Referral Contact:
James H. DoroshowJanelle Bingham
301-496-4291301-435-2715
jbingham@mail.nih.gov
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors
NCI-12-C-0056, NCT01519817

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors
NCI-12-C-0009, NCT01468922

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors
NCI-12-C-0008, NCT01439152

Principal Investigator:Referral Contact:
Raffit HassanYvonne Mallory
301-451-8742301-402-0255
malloryy@mail.nih.gov
Phase I Trial of NHS-IL12 in Subjects With Metastatic Solid Tumors
NCI-11-C-0225, NCT01417546

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
A Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin’s Lymphoma
NCI-11-C-0150, NCT01581541

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
NCI-11-C-0140, NCT01352962

Principal Investigator:Referral Contact:
Andrea B. ApoloLaura D. Otten
301-496-4916301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
NCI-11-C-0061, NCT01273168

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
NCI-11-C-0060, NCT01273155

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors
NCI-11-C-0029, NCT01245218

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women’s Cancers
NCI-11-C-0022, NCT01237067

Principal Investigator:Referral Contact:
Elise C. KohnLaura D. Otten
301-402-2726301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
NCI-10-C-0056, NCT01051635

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
NCI-09-C-0173, NCT00926640

Principal Investigator:Referral Contact:
Susan BatesChristine Bryla
301-402-5958301-451-7868
brylacm@mail.nih.gov
A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies
NCI-09-C-0111, NCT00923520

Principal Investigator:Referral Contact:
Susan BatesChristine Bryla
301-402-5958301-451-7868
brylacm@mail.nih.gov
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
NCI-09-C-0019, NCT01445509

Principal Investigator:Referral Contact:
Elise C. KohnLaura D. Otten
301-402-2726301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase 0
A Phase 0 Trial of [111] Indium CHX-A" DTPA Trastuzumab Imaging in Cancer
NCI-07-C-0101, NCT00474578

Principal Investigator:Referral Contact:
Peter ChoykeYolanda McKinney
301-402-8409301-443-6913
ymckinney@mail.nih.gov
No Phase
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
NCI-12-C-0175, NCT01658917

Principal Investigator:Referral Contact:
Udai KammulaCarole Webb
301-435-8606301-402-8475
Webbcc@mail.nih.gov
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy
NCI-09-C-0100, NCT00924027

Principal Investigator:Referral Contact:
Aradhana KaushalSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCI-97-C-0147, NCT00026884

Principal Investigator:Referral Contact:
W. Marston Linehan
301-496-6353



  
Trial and Protocol Number
Colorectal Cancer
Phase I/II
A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer
NCI-12-C-0187 , NCT01675128

Principal Investigator:Referral Contact:
Tim F. GretenSuzanne Fioravanti
301-451-4723301-594-6544
fioravas@mail.nih.gov


  
Trial and Protocol Number
Lung Cancer
Phase II
Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
NCI-12-C-0151, NCT01624090

Principal Investigator:Referral Contact:
David S. SchrumpTricia Kunst
301-496-2128301-451-1233
tricia_kunst@nih.gov
Phase I
Autologous Tumor Cell Vaccine and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to the Lungs, Pleura or Mediastinum
NCI-11-C-0148, NCT01341496

Principal Investigator:Referral Contact:
David S. SchrumpTricia Kunst
301-496-2128301-451-1233
tricia_kunst@nih.gov
Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum
NCI-11-C-0111, NCT01313429

Principal Investigator:Referral Contact:
David S. SchrumpTricia Kunst
301-496-2128301-451-1233
tricia_kunst@nih.gov


  
Trial and Protocol Number
Pediatric Cancers
Pilot
A Pilot Study of Tumor Vaccination and RHIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors
NCI-07-C-0206, NCT00923351

Principal Investigator:Referral Contact:
Crystal MackallPediatric Oncology
301-402-5940301-496-4256
1-877-624-4878 (Toll free)

Phase I/II
Phase I/II Trial of Mithramycin In Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWS-FLI1 Fusion Transcript
NCI-12-C-0135, NCT01610570

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)

Phase I
A Phase I Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
NCI-12-C-0208, NCT01518413

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)

A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
NCI-11-C-0073, NCT01287104

Principal Investigator:Referral Contact:
Kristin BairdPediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)

Phase I Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
NCI-11-C-0053, NCT01141244

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)

Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
NCI-11-C-0047, NCT01259479

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)

Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo® (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer
NCI-10-C-0220, NCT01222780

Principal Investigator:Referral Contact:
Alan S. WaynePediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)

A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
NCI-10-C-0178, NCT01182896

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer
NCI-08-C-0007, NCT00556881

Principal Investigator:Referral Contact:
Melinda MerchantPediatric Oncology
301-443-7955 301-496-4256
1-877-624-4878 (Toll free)



Back to Top